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Basic Principles of Genetics 
  
“Everything is genetic (except trauma)” 
Francis Collins, meeting of the American Academy of Dermatology, 1995 
 
The completion of the human genome sequence, with an estimated size of 3.2 
gigabases (Gb) and around 30000-35000 genes1,2, presents a powerful tool in medicine, 
facilitating and speeding the identification of disease genes. 
 The rapid advance in the development of molecular biology techniques, together with 
the continuing flow of information and tools derived from the human genome project, puts the 
physician in a privileged position, having direct access to the genetic basis of disease. It is 
important, thus, for the physicians in general and dermatologists in particular, to understand 
the basic concepts of genetics, as well as to be familiar with the new techniques to correctly 
offer and interpret the results to their patients. The wealth of new information also emphasizes 
the necessity of combined efforts among the clinical and research arms of medicine. 
 Access to patients with genetic disorders and accurate clinical description is essential 
for a research study aimed at the identification of a disease-causing gene. The benefits that 
disease gene identification can contribute to medicine are numerous. Its chief importance in 
genetic counseling and prenatal diagnosis has already been shown. But it can also contribute 
to the identification of carriers, identification of at-risk individuals by population screenings, 
presympomatic diagnosis, prediction of possible complications and course of the disease, 
response to pharmacological therapy and finally, to the eventual development of a treatment. 
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 In the last two decades, the molecular bases for numerous genetic disorders have been 
identified, such as epidermolysis bullosa (EB; chapter 34), ectodermal dysplasia (ED), 
Netherton syndrome or atrichia with papular lesions (APL). Although they do not account for 
the majority of patients in a dermatologist practice, they have helped to set the basis for the 
study of more common disorders, such as atopic dermatitis. These more common disorders 
can be major public health issues, but have a considerably more complex etiology. The gene-
identification strategies developed for more simple diseases, and the identified genes 
themselves, have played a major role in the study of the underlying causes of common 
complex disorders. The clinician has had and will have a key role in the feasibility of such 
studies, completely dependent on a large and well-characterized collection of patient samples. 
 
1. Basic Concepts in Genetics 
 
 In this section we provide some definitions to cover the basic concepts used in human 
genetics. 
 The nuclear DNA is packed into chromosomes and it is selectively folded and 
unfolded to allow the expression of hundreds of genes at different times and in different cell 
types. Somatic and germline cells contain around 2 meters of DNA3, which gives an idea of 
the packaging level of the DNA. We all inherit one set of chromosomes from our father and 
one from our mother. The paternal and maternal gametes are haploid cells, with only one 
chromosome complement or n (n=23), whereas the resulting embryo is a diploid cell, with 
two chromosome complements or 2n (2n=46). Each pair of chromosomes is composed of two 
homologous chromosomes, one from each parent. A chromosome complement consists of 23 
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chromosomes, with 22 pairs of autosomes and one pair of sex chromosomes (XX in females 
and XY in males). Chromosomes X and Y share only two small regions known as the 
pseudoautosomal regions. The karyotype describes the chromosome constitution of an 
individual. 
The centromere of a chromosome is the site of a primary constriction that is essential 
for correct cell division. It is composed of a series of proteins called histones and of repetitive 
DNA, which can reach several thousand kilobases (Kb). The centromere divides the 
chromosome into two arms, the short arm or p, and the long arm or q. According to the 
position of the centromere, the chromosomes can be classified as metacentric, with the 
centromere near the middle, resulting in two arms more or less equivalent in length; 
submetacentric, with the centromere between the center and the end, with two arms of 
different lengths; and acrocentric, with the centromere near the end and the two arms with 
considerably different lengths. The telomere constitutes the end of each chromosome and it is 
formed by thousands of repetitions of the DNA sequence TTAGGG, as well as proteins. They 
play a key role in the maintenance of chromosome integrity, as well as ensuring a correct 
chromosome replication. 
Meiosis is the process of cell division by which a diploid cell from the germline gives 
rise to haploid gametes. It results in a new combination of chromosomes in the daughter cells, 
as compared to that in the progenitor cells. Mitosis, on the other hand, is the process of cell 
division of proliferating cells by which the genetic material of a cell is duplicated and equally 
distributed among the two resulting daughter cells. To achieve this duplication of the genetic 
material, each chromosome duplicates itself resulting in two sister chromatids. Each of the 
sister chromatids will become the chromosome of the daughter cell. 
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 The location of a particular sequence of DNA on a chromosome, a gene or any 
fragment of DNA, is designated as a locus (plural, loci). Since we have two copies of each 
chromosome, we also have two copies of each locus. These two copies can be identical in the 
two homologous chromosomes, or they can display some differences. These alternative forms 
of a particular DNA sequence or gene are called alleles. An individual will have two alleles at 
any given autosomal locus, one from each parent. These two alleles will be identical in a 
homozygous individual or locus, and different in a heterozygous individual or locus (Fig. 1). 
Since males have only one copy of the X and Y chromosomes, they will be hemizygous for 
loci on these two chromosomes. Although an individual will have only two alleles for any 
given autosomal locus, being homozygous or heterozygous, when the population at large is 
considered, a particular locus may exhibit more than two alleles. By convention, when a locus 
exhibits at least two alleles with the frequency of one of them in the general population being 
greater than 1%, it is known as a polymorphism. They can be located inside or outside a gene. 
It has been estimated that single nucleotide polymorphisms or SNPs, which are only one class 
of polymorphic sequences, occur on average every 1000-2000 nucleotides4. The total length 
of the human genome, 3.2 Gb gives an idea of the great possible genetic variability, 
emphasizing the singularity of each individual’s genetic information. 
 
Fig. 1 Example of a polymorphic locus. 
 
The alleles present at a specific locus (or in the whole genome) constitute the genotype 
of an individual and the manifestation of a particular genotype and the environment in which 
it is expressed is the phenotype. Different genotypes are not always recognizable as distinct 
   7 
phenotypes. The genetic variation that results in the different alleles at a given locus arises by 
mutational events at the DNA level, which may or may not result in differences in the 
phenotype. If there is a change in the phenotype, this can be caused by variation (alleles) 
present in the general population (normal variation) or by pathogenetic variation leading to a 
disease. Although any change in the DNA is a mutation, regardless of the resulting 
phenotype, if any, the terms polymorphism and mutation tend to be used in human genetics 
to refer to normal variation present in the general population versus variation resulting in a 
disease phenotype, respectively. It is important to note, though, that this use of the terms 
mutation and polymorphism is not strictly correct. 
 
2. Genetic diseases 
 
 Although genetic diseases may manifest themselves in several members of a family, 
this is not the case for all of them. Likewise, it is not true that any disease manifested in more 
than one family member is genetic. Pedigrees in which a genetic disease is transmitted, i.e. 
segregates, can be present in either one single affected member or up to several generations 
with many affected members in each generation. 
 These genetic diseases may be caused by genetic defects in one gene (Mendelian or 
monogenic diseases) or more than one gene (polygenic diseases), but they can also be the 
result of the interaction of environmental and genetic factors (multifactorial diseases). In 
other cases, an aberrant structure or number of one or more chromosomes or a differential 
parental chromosomal contribution can be the cause of the disease. 
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In the following sections, we provide an overview of the different types of genetic 
diseases. 
 
3. Mendelian Diseases: Patterns of Inheritance 
 
A key initial step in the assessment of the risk for each individual from a family with a 
particular inherited disease is the establishment of the mode of inheritance of the condition. 
For this purpose it is essential to collect very accurate information on the clinical phenotype 
and to examine as many family members as possible to define their status, affected or 
unaffected. The family is usually ascertained through one family member, the proband, from 
whom the pedigree is built with the information on the phenotype and the relationship among 
every individual. 
 Even when a single gene defect is enough to cause a disease phenotype (monogenic 
disorders), its expression can be highly variable (see sections 4.1 and 4.2 for incomplete 
penetrance and variable expression). Genes are expressed on a particular genetic background, 
which is different in every individual, and these genes and their products interact with other 
genes and proteins. Thus, one can expect that even monogenic disorders may show some 
extent of variability. If a gene can be subject to different genetic backgrounds in different 
individuals and if this genetic background can modify its expression, then slightly or even 
considerably different clinical entities can be due to mutations in the same gene, known as 
allelic heterogeneity. This term also refers to those diseases caused by different mutations in 
the same gene. On the other hand, one could expect that defects in different components of 
the same metabolic pathway, for example, could result in the same phenotype, known as 
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genetic or locus heterogeneity. Thus, a diagnosis based on pure clinical symptoms can lead to 
misclassification of a patient, which underscores the relevance of the identification of disease 
genes. 
There are several examples of both allelic and locus heterogeneity in dermatology. 
Mutations in the GJB3 gene coding for connexin 31, for example, can result in autosomal 
dominant erythrokeratodermia variabilis (EKV) and autosomal dominant or recessive 
deafness. At the other end, epidermolysis bullosa simplex (EBS) of the Koebner type can 
result from mutations on the genes for keratin 14 or keratin 5. Figures 2 and 3 show examples 
of allelic and locus heterogeneity in skin disorders. Some diseases, such as EBS, display both 
allelic and locus heterogeneity. 
 
Fig. 2 Examples of allelic heterogeneity in genodermatoses 
 
Fig. 3 Examples of genetic or locus heterogeneity in genodermatoses 
 
Once a phenotype is defined, including its range of variability, the disease phenotype 
can be followed along the pedigree. The transmission of the trait in the pedigree will define of 
the pattern of inheritance of the disease. The genes responsible for monogenic traits can be 
located either on autosomes, defining an autosomal phenotype, or on the X chromosome in 
the case of an X-linked phenotype. Irrespective of the location of the gene, when a mutation 
in one allele is enough for the phenotype to arise, the trait is dominant. On the contrary, when 
both alleles of a gene must be mutated in order to alter the phenotype, the condition is called 
recessive. Thus, a phenotype can be inherited as an autosomal dominant or recessive trait or 
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as an X-linked dominant or recessive trait. There are also Y-linked genes, normally affecting 
male fertility25-27, although their relevance in more general diseases is discussed. 
It is important to note that although this chapter is focused on genodermatoses, all the 
statements for Mendelian or complex traits apply to both normal and disease phenotypes. 
 
3.1. Autosomal Dominant Inheritance 
 
 In a pedigree with an autosomal dominant disease, each affected person has an 
affected parent, both sexes are equally affected, and both sexes can transmit the trait; and 
there is transmission from generation to generation (Fig. 4A). 
 A single mutant allele is enough to give rise to the phenotype. Thus, the offspring of 
an individual with an autosomal dominant disorder have a risk of 50% (or 1 in 2 children) of 
inheriting the mutant allele. 
 An autosomal dominant trait can be transmitted from male to male and it cannot be 
transmitted by an unaffected individual (see section 4.1 for incomplete penetrance). Examples 
of autosomal dominant skin diseases are EBS, Darier-White and Hailey-Hailey diseases, 
monhilethrix or autosomal dominant ichthyosis vulgaris (chapter 57). 
A patient with an autosomal dominant disease is usually heterozygous for the disease-
causing mutation. Although not very often, homozygotes for autosomal dominant diseases 
have been reported, which usually exhibit a more severe phenotype compared to 
heterozygotes. An example of this latter is the case of a family with mutations in the KRT14 
gene, which in heterozygosis gives rise to autosomal dominant EBS of the Weber-Cockayne 
type and in homozygosis results in the more severe EBS of the Koebner type28. 
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There are, however, exceptions to the rules stated above, mainly explained by 
incomplete penetrance (section 4.1), variable expression (section 4.2), or de novo mutations 
(section 4.4). 
 
Fig. 4 Examples of Mendelian patterns of inheritance. 
 
3.2. Autosomal Recessive Inheritance 
 
 In a pedigree with an autosomal recessive disease, an affected individual has clinically 
unaffected parents; both sexes are equally affected; and there is no transmission from 
generation to generation (Fig. 4B). 
 Both alleles of a given gene have to be mutated for the disease to develop. The 
recurrence risk for the offspring is 25% (or 1 in 4 children). APL (a rare form of total 
alopecia) and Naxos disease (woolly hair, palmoplantar keratoderma and heart disease) are 
examples of autosomal recessive genodermatoses. 
 There is an increased frequency of consanguinity (sharing a common ancestor) among 
families with recessive conditions. Consanguineous matings increase the probability that a 
mutated allele present in the common ancestor will become homozygous in the offspring of 
the related parents (homozygosity by descent, section 4.6). When more than one affected 
family member for an autosomal recessive disease is present in a single pedigree, they are 
usually part of the same generation. But the presence of consanguinity can also explain some 
pedigrees in which an autosomal recessive trait is observed in more than one generation 
(section 4.6). 
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A patient with an autosomal recessive disease has inherited two copies of the disease-
causing mutation, while both parents are heterozygotes for the mutant gene, i.e. they are 
carriers of one mutant and one normal copy. Both parents can carry the same mutation, thus 
the patient will be homozygous for the disease-causing mutation, or they can carry two 
different mutations affecting the same gene, and the patient will be compound heterozygous. 
Exceptions to these statements are seen in inbred populations, in which matings 
between unaffected carriers and affected patients give rise to affected family members in two 
consecutive generations (pseudodominant inheritance, section 4.7). 
 
3.3. X-linked Recessive Inheritance 
 
 An X-linked recessive disease typically affects males, who will usually have 
unaffected parents; there is no male-to-male transmission; and the trait does not appear in 
successive generations (Fig. 4C). 
 The recurrence risk for the offspring will depend on the parent transmitting the disease 
allele. An affected father will transmit the mutated allele, but not the trait, to all his daughters, 
but to none of his sons. All the daughters of an affected male will be obligate carriers, since 
they will all inherit the mutated allele from the father. An obligate carrier female will transmit 
the mutated allele to 50% of her children. Thus, sons of a carrier mother will have a chance of 
being affected of 50%, while none of the daughters will be affected. 
 The two main characteristics of an X-linked recessive trait are the absence of male-to-
male transmission and the female carriers being asymptomatic. One main exception is the 
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offspring of an affected male and a carrier female. Other exceptions where carrier females 
might be affected involve non-random X-inactivation (section 4.3). 
 Examples of recessive X-linked diseases in dermatology are X-linked ichthyosis (or 
steroid sulfatase deficiency; chapter 57) and anhidrotic ectodermal dysplasia (EDA). 
 
3.4. X-linked Dominant Inheritance 
 
 In a pedigree with an X-linked dominant disease, affected individuals have at least one 
affected parent; it affects both males and females, although affected females are more 
common than affected males, but have a milder phenotype; there is no male-to-male 
transmission; and the trait appears in successive generations (Fig. 4D). 
 The recurrence risk for the offspring will depend again on the transmitting parent. An 
affected father will transmit the trait to all his daughters, but to none of his sons. An affected 
female, on the other hand, will transmit the trait to 50% of her children, regardless the sex of 
the offspring. 
 Although both sexes can be affected, the trait is usually milder in females than in 
males due to non-random X-inactivation (section 4.3). Examples of an X-linked dominant 
disease for which females present with a less severe phenotype are focal dermal hypoplasia 
(DHOF or Goltz syndrome)34 and incontinentia pigmenti 35. Females affected with DHOF 
present with cutaneous, skeletal, dental, ocular, and soft-tissue defects, whereas for males, 
lethality in uterus is suspected. 
 
   14 
3.5. Y-linked Inheritance 
 
 In a pedigree with a Y-linked disease (holandric inheritance), affected males always 
have affected fathers and only males are affected. All sons of affected males are affected (Fig. 
4E). 
There have been only a few reports on Y-linked diseases, and most of them affect 
male fertility25-27. A few examples affecting other organs have been described33, although their 
Y-linked inheritance cannot be proven  
 
4. Exceptions to Basic Mendelian Inheritance Patterns 
 
 By definition, Mendelian diseases are the result of mutations in one single gene. But, 
as mentioned above, this gene can modify and be modified by other genes and by the 
environment. Thus, although the presence of the genotype at one single locus will still be 
responsible for the disease phenotype, the final phenotype can be subject to variation in its 
expression. The following sections (4.1 to 4.10) describe single-gene defects that by means of 
variability in the expression of the mutant allele or by the location of the mutant gene 
constitute apparent or real deviations to the basic Mendelian patterns of inheritance outlined 
above. 
 
4.1. Incomplete or Reduced Penetrance and Late Onset Diseases 
 
   15 
 As defined above, a carrier of a dominant mutation or a homozygote (or compound 
heterozygous) for recessive mutations will manifest the disease phenotype. This is true for 
many genetic traits, but there are some exceptions to this rule. In terms of genetic counseling, 
these exceptions can present a dilemma. 
 Incomplete or reduced penetrance refers to those situations where not all the 
individuals who carry the disease genotype manifest the condition. In these cases, the value of 
the penetrance will indicate the probability of an individual with the disease genotype to 
develop the disease phenotype. It is important to note that penetrance refers to an “all or 
nothing” event, in which some individuals who have inherited the disease genotype do not 
express the disease phenotype at all. An example of the result of incomplete penetrance would 
be an autosomal dominant pedigree with an affected individual, unaffected parents, but an 
affected grandparent. As a consequence, the trait appears to “skip” a generation (Fig. 5A). 
 A particular case of incomplete penetrance is the so-called late onset diseases, 
characterized by age-dependent penetrance. Some diseases exhibit complete penetrance, but 
only starting from a certain age. In the case of congenital diseases, the trait becomes manifest 
from birth. But there are many other diseases where the symptoms appear later in life. Darier-
White and Hailey-Hailey diseases are good examples, in which the main features of the 
disease develop around early adulthood and second to fourth decade, respectively (chapter 
59)36,37. 
Age-dependent penetrance presents another difficulty for genetic counseling and, in 
general, for the establishment of the inheritance pattern of a trait, since some individuals may 
be too young for a definitive diagnosis. 
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Fig. 5 Examples of complications to the basic Mendelian patterns of inheritance. 
 
4.2. Variable Expression 
 
 A disease genotype can fail to manifest itself completely (reduced penetrance), but it 
can also manifest in every individual with the disease genotype, but with variation in the 
severity of symptoms. This variation in the expression of a genotype can be interfamilial 
(between families) or even intrafamilial (within a family). The variable degree in which a 
particular genotype is expressed as a phenotype is called variable expression. Darier-White 
disease, for example, displays complete penetrance in adults, but the severity of the cutaneous 
manifestations can be variable (chapter 59)40. 
 The variable expression of some traits manifest as a tendency to increase in severity 
and decrease in the age of onset through successive generations. This phenomenon is referred 
to as genetic anticipation and it offers an additional challenge in genetic counseling. The 
molecular basis of genetic anticipation is now known. Certain genes show a variable number 
in the repetition of a three nucleotide sequence, known as trinucleotide. These repeats range in 
number in the general population, as part of the normal variation. Through a yet unknown 
mechanism (DNA polymerase “slippage” has been hypothesized), the number of these repeats 
can increase dramatically and enter the disease-associated range, where the number of repeats 
become unstable through successive generations. In general, the number of repeats within this 
range tends to increase through generations, although it can also decrease. The severity and 
age of onset of the resulting phenotype correlates with the length of the repeat. The paradigm 
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of genetic anticipation is myotonic dystrophy, with a “cascade of mild, adult, childhood, or 
congenital disease in subsequent generations”41. 
 
4.3. X-inactivation 
 
Although females have a double dose of the X chromosome as compared to males, for 
most of the X-linked genes (except those present in the pseudoautosomal region) any 
particular cell in a female has only a single active X chromosome. The mechanism of X-
inactivation or lyonization is responsible for this dosage compensation in females. During 
embryonic development, one of the two X chromosomes in each cell is randomly inactivated. 
From this stage on, all the derived cells will have the same inactivated X chromosome as their 
progenitor cell. As a result, a female has two alleles for every gene located in the X 
chromosome, but a given cell expresses only one of them. If one of these alleles happen to 
contain a disease-causing mutation, the resulting phenotype in the female will depend on the 
proportion of cells expressing that mutated allele in a particular tissue. This explains why 
female carriers for X-linked recessive mutations can manifest some symptoms of the disease, 
whereas an X-linked dominant phenotype in females is usually milder than in males. As an 
average, each allele of an X-linked gene is active in half of the cells in a female. But this 
proportion can be variable, also explaining why the expression of X-linked dominant traits is 
more variable in females than in males. In fact, it can range from a completely normal 
phenotype to a full spectrum of the disease phenotype. 
There are exceptions, however, where a particular X-chromosome is preferentially 
inactivated, known as skewed or non-random X-inactivation. Affected females with 
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incontinentia pigmenti type II (IP2) show highly skewed X-inactivation, suggesting a negative 
selection against cells with an active IP2 mutant allele35. Non-random X-inactivation in 
different hematopoietic cells has also been proved in obligate carrier females with 
dyskeratosis congenita42. 
Other situations prone to non-random X-inactivation are the X:autosome 
translocations. The normal X-chromosome is usually inactivated in the presence of a balanced 
X:autosome translocation to avoid monosomy for the genes on the translocated autosome. 
This is thought to be the explanation for affected females for X-linked recessive diseases. 
Such is the case for anhidrotic ectodermal dysplasia (EDA) in carriers of a t(X;9) 
translocation43. 
 
4.4. De novo Mutations 
 
The different alleles for a locus present in the population, responsible for both normal 
variation or disease phenotypes, arise by mutational events in the DNA. This phenomenon can 
be observed in pedigrees in which a genetic disease appears with no previous family history 
for that condition. When this is the case, an affected child is born from unaffected parents 
who do not carry the mutation. De novo mutations occur during meiosis in one of the parents 
and are usually more common in severe diseases, with a marked decreased reproductive 
fitness. The identification of de novo mutations can have a profound impact in genetic 
counseling. A family with one single affected offspring is usually suspected to have a 
recessive condition, and thus, a risk of 25% for another affected child. The likelihood of the 
patient having affected offspring will be the same as in the general population. If, on the 
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contrary, the pedigree with one single affected individual is due to a de novo mutation, there 
is no recurrence risk for the generations of the parents and the siblings of the affected child, 
since a second de novo mutation at the same gene would be highly unlikely. However, the 
affected individual will transmit the mutation to 50% of its offspring, and therefore it will 
behave as a typical dominant trait. An exception to the recurrent risk for a de novo mutation is 
the case of mosaicism (section 4.5; chapter 62). 
De novo mutations have been identified in different types of epidermolysis bullosa 
(EB). In dystrophic EB (DEB), for example, the same de novo mutation, Gly2043Arg, in the 
type VII collagen gene, COL7A1, has occurred independently throughout the world44. 
 
4.5. Mosaicism and Chimerism 
 
A general form of mosaicism is that involving X-inactivation in females, with each 
cell expressing the genes from one single X-chromosome. But mosaicism can also refer to 
pathogenetic situations. 
When a de novo mutation first appears in a pedigree, the recurrence risk for a second 
affected child is extremely low. But there are some instances in which a second affected child 
is born unexpectedly, although a de novo mutation was initially suspected. This is usually due 
to gonadal or germline mosaicism (chapter 62). When a mutation or chromosomal 
abnormality occurs in a cell during embryonic development, its descendent cells will carry the 
same mutation. On the contrary, the rest of cells, not affected by the mutation, will carry the 
wild-type (nonmutant) allele. The result of this mutational event will be an individual with 
two different cell populations. Although the mutation present in one of these populations can 
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affect one single gene, its behavior will differ from that of a typical Mendelian mutation. The 
location of the cell and the timing of the mutational event during development will determine 
the extent and distribution of the cells carrying the mutation. If a de novo dominant mutation 
occurred after the separation of the germline and somatic cell lineages and it took place in the 
latter, the gonads will not carry the mutated allele, and the risk for the offspring will be 0. On 
the contrary, if the mutation took place in a germline cell or precursor, a proportion of the 
resulting gametes will carry the mutated allele. In the first affected generation, the trait will 
mimic an autosomal recessive trait, since the affected children will be born from unaffected 
parents. But the trait will be inherited as a classical autosomal dominant trait in successive 
generations, as stated above for de novo mutations. The key information for genetic 
counseling will be to know whether the mutation is present in the germline of the mosaic 
individual. The extent of involvement of the gonads will determine the recurrence risk for the 
offspring. 
Maternal germline mosaicism has been demonstrated in DEB, for example. A 
mutation was identified in an affected child born to unaffected parents 45. Since the mutation 
was present only in the patient, while absent in the unaffected parents, the mutation was most 
likely a de novo event. However, the possibility of germline mosaicism was considered and 
prenatal diagnosis was performed for the next pregnancy. The results indicated that the fetus 
had, in fact, an identical mutation, indicating germline mosaicism in one of the parents. These 
findings have significant impact when counseling on the recurrence risk for affected 
offspring. 
When mosaicism affects the skin, it can become apparent by the appearance of 
different cutaneous patterns, such as the lines of Blaschko (chapter 62)46,47. 
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Genetic mosaicism affecting the skin has been classified in two types. Type I refers to 
the type of mosaicism delineated above, where the segmental affected skin is thought to carry 
the mutant allele, while the genotype of the skin outside the affected areas is thought to bear 
the wild-type allele. But there are examples where this segmental manifestation of the disease 
is expressed over a more diffused and milder involvement of the same phenotype. This is 
referred to as type II involvement. It has been hypothesized that an individual with a type II 
involvement would have a heterozygous dominant mutation in the germline, giving rise to the 
diffuse phenotype, and that a second mutation would inactivate or delete the wild-type allele, 
resulting in the segmental and more severe phenotype. 
There are several examples of somatic mosaicism affecting the skin, such as epidermal 
nevus, Darier-White disease, neurofibromatosis, multiple cutaneous leiomyomatosis or linear 
porokeratosis superimposed on disseminated superficial actinic porokeratosis48-52. 
Finally, the different populations of cells present in a mosaic are thought to derive 
from a single zygote. In contrast, there are examples of individuals with cell populations with 
a complete different genetic composition. These are known as chimeras, and the different cell 
populations are thought to derive from different zygotes. 
 
4.6. Inbreeding 
 
Inbreeding is one of the factors that can modify the frequency of alleles in a 
population, increasing the number of homozygotes. When a mating occurs between two 
individuals who share a common ancestor, this mating is referred to as consanguineous. 
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A recessive mutation can be passed on through generations in the heterozygous state. 
If a carrier for a recessive mutation has children with a second carrier of another recessive 
mutation in the same gene or even the same mutation, their children will have a 25% 
likelihood of inheriting both mutant alleles. Recessive disorders are not very frequent, since it 
requires these two carriers to mate. But in inbred populations, the probability that two carriers 
of the same mutation originating from a common ancestor mate is significantly higher. This is 
the explanation for the increased incidence of consanguinity among autosomal recessive 
diseases. The affected offspring from a consanguineous mating will be homozygous for the 
same mutation and also for the region surrounding that mutated gene, representing two copies 
of the same chromosomal region travelling from the common ancestor, down through 
different branches of the family and coming together again in the consanguineous mating. The 
affected offspring is called homozygous by descent, reflecting the fact that both mutant alleles 
are copies from the same ancestral mutant allele. The more common a mutant allele is, the 
less incidence of consanguinity is observed in that disease, and vice versa. When a pedigree is 
ascertained with only one affected family member, the presence of consanguinity in the 
parents of the affected is suggestive of an autosomal recessive condition. 
When building a pedigree, it is important to consider the possibility of consanguinity, 
even if denied by the parents, if these come from a small geographical area.  
Since in an inbred population there is a higher probability for two persons to be 
related, it will also be possible that this can happen more than once in the same pedigree. In 
these situations, one can find affected individuals in different generations of a kindred, 
simulating an autosomal dominant trait (Fig. 5B). 
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Most of the considerations applied above for consanguineous matings can also be 
applied to isolated populations, such as the Finnish, the Icelandic or the French-Canadian 
populations. They usually derive from a small group of ancestors and are subject to 
geographical or linguistic isolation. If one of the ancestors was a carrier for a particular 
mutation, it will be overepresented in the present population. This effect, known as founder 
effect, is the explanation for the fact that some diseases or mutations are present at very 
different frequency in isolated populations when compared to other groups. 
In South Africa, for example, a large proportion of the present population descends 
from a small number of Dutch settlers and, in fact, the high proportion of cases of porphyria 
(chapter 50) variegata have been traced back to a few settlers in the 17th century53. 
 
4.7. Quasidominant or Pseudodominant Inheritance 
 
There is another situation where the inheritance of a recessive trait mimics an 
autosomal dominant pattern (Fig. 5C). This is the case for matings between an affected 
individual for a recessive trait and an unaffected carrier for the same or a different mutation in 
the same gene. In these situations, the offspring has a 50% probability of inheriting two 
mutant alleles. Although this is the same risk as for an autosomal dominant trait, this parent-
to-child transmission does not occur in successive generations, unless the unlikely event of a 
second mating between a homozygote and a heterozygote. Instead, the risk of having an 
affected child became as low as for the general population. These situations can happen in 
both inbred and outbred populations, although the probability of such matings is increased in 
the first ones.  
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An example of pseudodominant inheritance has been reported in a family in which a 
mother and a son were affected with APL, suggesting dominant inheritance, whereas APL is 
commonly inherited as an autosomal recessive disease. The molecular analysis revealed, in 
fact, that both the affected mother and son were homozygous for mutations in the same gene, 
in accordance for the recessive nature of the disease 39. 
 
4.8. Imprinting 
 
Up to now, we have been discussing recurrence risk depending only on whether an 
individual has inherited the disease-associated genotype. But some genes are subject to an 
additional level of regulation by epigenetic phenomena: the sex of the transmitting parent will 
determine whether that gene will be expressed in the offspring, known as imprinting. The 
phenomenon of imprinting influences the assessment of recurrence risk in genetic counseling. 
The risk for a parent of transmitting a mutated allele remains the same, 50%, for females and 
males, but the probability that the mutated allele will be expressed in the offspring will differ 
depending on the sex of the transmitting parent. These sex specific alterations involve DNA 
methylation. 
 The effect of imprinting is especially apparent in the case of uniparental disomy 
(UPD), where both homologous chromosomes are derived from the same parent, instead of 
one from each parent. In heterodisomy, the two homologues from the same parent are 
inherited, as opposed to isodisomy, where one chromosome from one parent is duplicated. 
UPD can go undetected for some chromosomes. For others, it can result in a disease 
phenotype, such UPD for chromosome 15 in Prader -Willi and Angelman syndromes. 
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 The appearance of UPD affecting recessive mutant alleles can bring the mutation to 
homozygosis in affected individuals. The Herlitz variant of junctional epidermolysis bullosa 
(H-JEB), also an example of locus heterogeneity, can be caused by mutations in one of the 
three genes coding for the different subunits of laminin, LAMA3, LAMB3 and LAMC2. Both 
paternal and maternal UPD have been described in H-JEB patients. In two independent 
pedigrees, a complex combination of maternal uniparental hetero- and isodisomy resulted in 
homozygosity of a maternal LAMB3 mutation in the affected child54,55. In a third case, paternal 
uniparental isodisomy resulted in a patient homozygous for a paternal LAMC2 mutation56. 
 
4.9. Loss of Heterozygosity 
 
There are some disorders in which the susceptibility for the development of certain 
tumors is inherited as a Mendelian trait. In these cases, affected individuals usually carry a 
germline mutation in a tumor suppressor gene, involved in the regulation of cell growth. 
Inactivating (loss-of-function) mutations in both alleles of a tumor suppressor gene can 
contribute to tumor formation. These familial cases are, therefore, at a higher risk of 
developing a tumor, since a single somatic mutation inactivating the second, normal allele of 
the same gene, can trigger tumor formation. For this reason, inherited forms of cancer 
susceptibility can result in the development of multiple tumors in the same individual, as 
opposed to the single tumors found in the sporadic cancers. When studying these tumors, the 
usual finding is to identify two mutations in the two alleles of the gene. One of them will 
correspond to the germline mutation, whereas the second one will be a new somatic mutation, 
referred to as the “two-hit hypothesis”57. One common type of somatic mutation found in 
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tumors is known as loss of heterozygosity (LOH). When analyzing the DNA of tumor 
samples from an individual heterozygous for specific polymorphisms (usually microsatellites, 
section 6.1.1), the results from the tumor can show homozygosity for one single allele, 
instead. This phenomenon is known as LOH. Advanced tumor cells can show extensive LOH 
through the genome, however, there are certain regions for which LOH is common to several 
tumors. This usually happens in the vicinity of tumor suppressor genes. 
 
4.10. Mitochondrial Inheritance 
 
Mitochondrial inheritance is another example of a single gene defect that does not 
follow a classical Mendelian pattern of inheritance. Each cell has many mitochondria, each of 
them containing one or more copies of the mitochondrial genome, a 16-kilobase (Kb) circular 
DNA molecule. Only mothers pass mitochondria to the offspring, thus there is no paternal 
complement. During cell division, mitochondria will segregate randomly to each of the two 
daughter cells. Thus, if a mother carries a mutation in one gene located on the mitochondrial 
chromosome in only some of her mitochondria, the daughter cells can inherit a variable 
number of organelles carrying the mutation. A situation where all mitochondria carry the 
mutation is known as homoplasmy, versus heteroplasmy, referring to a mixture of 
mitochondria carrying the normal or the mutant version. The resulting phenotype will depend 
on the proportion of mutant and normal mitochondria in a specific tissue. 
The result of mitochondrial inheritance is a pedigree where both females and males 
can be affected, but only females transmit the disease trait. The proportion of affected 
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children seems to be random, and there is a high degree of variability in the expression of the 
phenotype. 
 As an example, a transition from adenine (A) to guanine (G) at position 7445 of the 
mitochondrial DNA, affecting the gene encoding the tRNA for serine, has been identified as 
the cause for a form of palmoplantar keratoderma with or without sensorineural deafness. In 
these pedigrees the disease presents with incomplete penetrance and with varying severity58-62. 
 
4.11. Phenocopy 
 
A phenocopy refers to those phenotypes caused by environmental factors that mimic a 
similar phenotype caused by genetic mutations. Porphyria cutanea tarda (PCT), for example, 
is an autosomal dominant disease caused by mutations in the URO-D gene, encoding the 
uroporphyrinogen decarboxilase. Affected patients are predisposed to light-sensitive 
dermatitis. It has been shown, however, that a similar phenotype can be caused by exposure to 
certain chemicals. Between 1955 and 1961, in fact, around 3000 patients developed PCT in 
Turkey. The cause was determined to be exposure to hexachlorobenzene, used to preserve the 
wheat seeds. PCT has also been reported in individuals with industrial exposure to certain 
hydrocarbons63, as well as in workers exposed to some pesticides64. 
 
5. Chromosome Disorders 
 
In the above sections, the disease-causing mutation affects a single gene. But this is 
not always the case. Around 65% of the spontaneous abortuses studied, for example, exhibit 
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chromosome anomalies65, which can involve one or more genes contained in the affected 
region.  
Chromosomal abnormalities can result in abnormalities in the number or in the 
structure of the chromosomes. The differences in DNA composition along a chromosome 
have allowed the development of various banding techniques, which enable the identification 
of each particular chromosome in a karyotype, as well as the identification of chromosomal 
anomalies, both numerical or structural. In addition, the use of FISH (Fluorescent In Situ 
Hybridization), which can detect DNA sequences as short as 1 Kb3, allows the identification 
of very small changes in the chromosome constitution, not visible by the use of conventional 
banding techniques. 
Chromosomal numerical abnormalities can involve the whole genome, poliploidy or 
nullisomy, or just one pair of homologues, aneuploidy. 
The only forms of poliploidy observed in humans are triploidy, with three complete 
sets of chromosomes (3n), and tetraploidy, with four chromosome complements (4n). 
However, most polyploid embryos are spontaneously aborted. 
A particular case of cells with a different number of chromosome complement, yet 
viable and functional normal cells, is the case of the platelets and keratinocytes, which loose 
their nuclei and, as a consequence, are nullisomic. 
Aneuploidy, on the other hand, refers to the presence of an additional chromosome or 
its absence. The only observed aneuploidies are trisomies, with three copies of a single 
chromosome and, very rarely, monosomies. Trisomies for a whole chromosome are only 
observed for chromosomes 21 (Down syndrome), 18 (Edwards syndrome), and 13 (Patan 
syndrome). Regarding monosomies, only monosomy for chromosomes X (Turner syndrome) 
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and 21 have been observed, the latter being extremely rare. Partial trisomies or monosomies 
due to duplication, deletion or segregation of balanced translocations (section 5) can also be 
observed. 
Structural abnormalities involve breakage of chromosomes, instead of a change in 
chromosome number. Most chromosomal breaks are normally reconstituted by the repair 
enzymes. When this is not the case, however, the breaks result in structural abnormalities. 
They will be balanced if there is no net gain or loss of genetic material, or unbalanced, when 
they are accompanied by additional or missing genetic information. The stability of the 
resulting rearranged chromosome through cell division will depend on the presence of a 
centromere and two telomeres, the necessary elements for the correct segregation of 
chromosomes. 
Balanced chromosomal abnormalities include some types of translocations and 
inversions. In a reciprocal translocation, two breaks in two non-homologous chromosomes 
occur and the chromosomal segments distal to the break are exchanged. The total number of 
chromosomes remains the same. If the translocation breakpoint affects a gene or its regulatory 
sequence, or otherwise, places it under the control of novel regulatory elements, it can result 
in an observable phenotype. The main problem with reciprocal translocations arises in the 
offspring of the carriers. Depending on the combination of parental chromosomes inherited, 
they can result in partial trisomy and monosomy for the chromosomal regions involved in the 
translocation. 
Inversions are balanced rearrangements in which two breaks occur in the same 
chromosome and the intervening segment is inverted before the chromosome is reconstituted. 
In a pericentric inversion, the inverted segment includes the centromere, whereas in a 
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paracentric inversion, the two breaks happen in the same chromosome arm, without 
involvement of the centromere. 
There are only a few examples of chromosomal abnormalities underlying skin or hair 
disorders as their major clinical feature. EDA, for example, has been diagnosed in several 
patients with rearranged X chromosomes, such as X;autosome translocations or genomic 
deletions involving the EDA gene 66. Another example is Ambras syndrome, a unique form of 
congenital universal hypertrichosis (chapter 70). Although the molecular basis of the disease 
is still unknown, two unrelated cases have been reported with cytogenetic abnormalities 
involving one common chromosomal region, 8q22. One of the patients has a balanced 
pericentric inversion denominated (8) (p11.2, q22)67 and a second patient has the paracentric 
inversion (8) (q12, q22)68. Although the specific gene defect underlying Ambras syndrome is 
still unknown, the fact of having two independent chromosomal abnormalities involving the 
same chromosomal region and both in patients with the same rare disease suggests that the 
chromosomal region 8q22 contains a candidate gene or regulatory region responsible for the 
Ambras syndrome phenotype69. 
Regarding unbalanced chromosomal abnormalities, there are several mechanisms 
that can lead to a net gain or loss of chromosomal material. Deletions and duplications, for 
example, can be the result of the segregation of a balanced translocation, among other 
possible causes. 
 
6. Identification of Disease genes 
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As stated at the beginning of this chapter, disease gene identification is crucial for 
many areas of medicine, such as genetic counseling and prenatal diagnosis. There are two 
main approaches generally applied for the identification of the disease gene for a Mendelian 
disorder, in which a single mutated gene is expected to cause the disease phenotype. The 
approach will usually depend on the kind of information available on the particular trait. 
Functional cloning requires some previous knowledge about the defective function, 
but no positional information is required. When the abnormal function leading to the disease 
phenotype is known, such as the biochemical defect or the defective protein itself, several 
approaches can be applied to clone the corresponding gene. However, even though functional 
cloning has provided many of the cloned disease genes, its application is very limited, since 
there are only a few disorders for which the biochemical defect is known. When the pre-
existing information on the phenotype helps to point a particular gene, this gene becomes a 
candidate gene, which can be analyzed directly for its involvement in the phenotype. The 
candidate gene approach can use information on the defective pathway, function, structure or 
tissue underlying the phenotype. The expression of a gene (in the same tissues as those 
affected by the disease phenotype), its function (its role in a given metabolic pathway or 
cellular structure), its homology or relation to mutated genes responsible for close 
phenotypes, for example, can be a good starting point to choose a candidate gene. An 
additional and greatly helpful source of information are animal models. There are many 
examples, although also some exceptions, where closely related phenotypes in mice and 
human, for example, are caused by mutations in orthologous genes (referring to homologous 
genes in different species). 
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By means of the candidate gene approach, two separate groups identified mutations in 
the TGM1 gene as the molecular basis for lamellar ichthyosis (LI; chapter 57), an autosomal 
recessive disease of cornification70,71. TGM1 encodes the keratinocyte form of 
transglutaminase (TGK), involved in cross-link reactions during the formation of the cornified 
envelope. Huber at al analyzed the TGM1 gene following studies that showed decreased or 
absent activity and expression of TGK in LI patients. Russell et al, on the other hand, studied 
TGM1 and other genes on the basis of the role of the encoded proteins in the formation of the 
stratum corneum. 
For positional cloning, on the contrary, no previous knowledge on the defective 
function is required; it starts with the chromosomal assignment of the region containing the 
defective gene by means of linkage analysis. Positional cloning appears as a powerful tool in 
disease-gene identification, since for most of diseases the only information available is the 
observable phenotype segregating in pedigrees. 
 The identification of the gene responsible for the EDA phenotype is an example of 
positional cloning. The genetic locus was mapped to the chromosomal region Xq12-q13.1 by 
means of linkage analysis and translocations in female patients. After identifying putative new 
genes in the disease interval, Kere et al identified the EDA gene72. The location of the gene, 
the identification of mutations in the patients and its expression proved the pathogenetic role 
of the gene in the EDA phenotype. 
 The approach that have yielded more results, however, uses a combination of both 
functional and positional information. In the positional candidate approach, once the 
chromosomal location of the disease locus is known, functional information is utilized to 
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directly analyze the candidate genes contained in that particular chromosomal region (section 
6.1.3). 
 
6.1. Positional Cloning 
 
 When no information is available on the possible defective function or product, the 
first step for the identification of the disease gene is the mapping of the chromosomal location 
that most likely contains the gene, the disease locus. There are some instances where there is 
previous information on the location of the gene, such as the presence of chromosomal 
abnormalities or LOH in a patient, which can considerably accelerate the identification of 
disease genes. These chromosomal abnormalities are usually translocations, inversions, 
deletions or duplications. 
 The occurrence of X:autosome translocations in females affected with EDA and 
involving the same breakpoint on the X-chromosome helped to indicate the location of the 
causative gene. Eventually, a combination of linkage analysis, translocation breakpoints and 
small deletions in patients led to the identification of the ED1 gene, responsible for the EDA 
phenotype72. 
 In the same way, LOH can give a hint on where the disease gene might be. This has 
proven to be very useful in the identification of tumor suppressor genes. Familial 
cylindromatosis, for example, is characterized by multiple tumors of the skin appendages or 
cylindromas. The predisposition to develop the tumors is inherited as an autosomal dominant 
trait. Over 70% of the tumors show LOH in the vicinity of the gene that causes the disease 
and in all cases the allele lost in the tumors is the wild-type allele. Moreover, the tumors show 
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no other regions of LOH along the genome. In the example of cylindromastosis, linkage 
analysis combined with the presence of LOH led to the identification of the underlying 
mutated tumor-suppressor gene, PTEN73,74. 
 
6.1.1. Linkage Analysis 
 
For most of the disorders, however, there is no previous information on the defective 
function or possible location of the disease gene. In such situations, a linkage analysis 
approach is performed to map the location of the disease gene. The aim of linkage analysis is 
the identification of a chromosomal region that is transmitted along with the disease 
phenotype (co-segregates). When this region is found, the disease is said to be linked to that 
genetic locus. 
Gene mapping in general has proven to be very useful not only for the identification of 
the actual disease gene, but also for genetic counseling. Once the location of the gene is 
known, we can tract the disease gene in the families affected by following the inheritance of 
this chromosomal region. 
The requirements to perform a linkage analysis include a thorough definition of the 
phenotype, the availability of pedigrees with enough linkage information (power), the 
availability of a dense map of highly polymorphic markers and, finally, the application of 
statistical analysis. 
When defining the phenotype to be studied, it has to be considered that the 
correspondence between a gene and a disease is not always linear. There are numerous 
examples of allelic heterogeneity, with different mutations in the same gene resulting in 
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different phenotypes (Figure 2; section 3) and locus heterogeneity, in which the same or very 
close phenotypes are caused by mutations in different genes (Figure 3; section 3). 
Since the purpose of linkage analysis is mapping a single gene, it is extremely 
important to work with as homogeneous of a sample as possible to avoid locus heterogeneity. 
It is important, thus, to define clear-cut phenotypic classes. But this is not always possible for 
all diseases. Some close phenotypes are represented by a continuum of symptoms, rather than 
by clear-cut phenotypic classes. For others, the age of the individual can lead to misdiagnosis 
because of age-dependent penetrance, for example, or because of the progressive nature of the 
disease, in which the patient can be at a too early or a too advanced stage for the disease to be 
distinguished from close phenotypes. 
Finally, since in all these studies the disease gene is unknown and the phenotype itself 
will be used to track the disease gene along the pedigree, it is essential to know if special 
circumstances such as incomplete, age-dependent penetrance or phenocopies, for example, 
might be expected. 
Once the phenotype has been clearly established, a large enough sample needs to be 
chosen to achieve statistically significant results. Linkage studies are usually performed either 
on a single large pedigree, or on several smaller ones. The first approach ensures genetic 
homogeneity of the sample, but it may not be available for every disease, whereas the second 
introduces the unwanted possibility of locus heterogeneity, but is usually more common for 
the majority of diseases. 
With a large enough and well-characterized collection of samples, the linkage analysis 
itself can be performed. Linkage analysis, and genetic mapping methods in general, rely on 
genetic recombination or crossing-over. 
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The rationale is that the closer two loci are together, the less frequently they will be 
separated by recombination during meiosis. Loci very close together will rarely be separated 
by recombination, while recombination will occur between loci separated by a certain 
distance on the same chromosome, the larger the distance, the higher the frequency of 
recombination. A particular combination of alleles for several close loci on the same 
chromosome is known as haplotype (Fig. 6). Finally, and due to the independent assortment 
of maternal and paternal homologous chromosomes during meiosis, loci located on different 
chromosomes will segregate independently. 
 
Fig. 6 Examples of haplotypes for a chromosomal region containing four polymorphic 
loci, A, B, C and D. 
 
The frequency of recombination, or θ, between two loci will reflect the genetic and 
physical distance between them. A recombination fraction of 1% or 0.01 is equivalents to 1 
cM (cM: genetic distance measure unit). 
When linkage analysis is performed, the disease gene is unknown. The inheritance of 
the disease phenotype is compared to the inheritance of polymorphic loci or markers along 
the genome. The goal is to find one or more polymorphisms that are inherited in the same way 
as would be expected for the disease gene. The disease locus will be then linked to such a 
marker, which will allow us to follow the disease gene through the pedigree until it is actually 
identified. It is important to note that the linked marker is not necessarily the disease gene 
itself, but a closely linked locus. 
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There are many types of DNA polymorphisms, but not all of them are good markers 
for a linkage analysis. The two requirements are i) the informativeness and ii) the distribution 
of the polymorphisms. 
The informativeness of a polymorphism refers to both the number and allelic 
frequency of the different alleles at a given locus. The more informative a polymorphism is, 
the greater the chance for an individual to be heterozygous or informative for linkage. 
The two types of markers generally used in linkage analysis are microsatellites and 
SNPs (Single Nucleotide Polymorphisms) (Fig. 7A, B). Microsatellites are extensively used 
in linkage analysis. They consist on a tandem repetition of a 1-13 nucleotides unit sequence75. 
Dinucleotides are the most commonly used microsatellites, with a repeat unit consisting of 
two nucleotides, followed by tetra- and trinucleotides, four and three-nucleotide repeats. 
Among the dinucleotides, the (CA)n repeats are by far the most numerous. For the SNPs the 
polymorphism involves the presence of a given nucleotide at a particular position, while the 
polymorphism for microsatellites refers to their length, due to the variation in the number of 
repeats of the basic unit sequence (Fig. 7C). 
 
Fig. 7 Examples of different types of polymorphisms. 
 
The second requirement for a polymorphism to be a good marker in a linkage analysis 
depends on the density of the map. The longer the distance between two loci, the larger the 
sample needed to detect linkage. In a typical linkage analysis, markers spaced at about 10 cM 
and distributed along the entire genome are analyzed, in what is known as a genome-wide 
scan. This implies an average of 300 markers, analyzed using a very powerful technique 
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known as PCR (Polymerase Chain Reaction) that allows the analysis of a specific sequence of 
DNA by its exponential amplification. 
Once the data from a genome-wide scan is gathered statistical analyses are performed 
to give us an idea of how significant our results are. When the genome as a whole is analyzed, 
the possibility of false positives has to be considered, since more than one region that mimics 
the inheritance of the disease gene in a particular pedigree can be found, although only by 
chance. The statistical value used is the LOD score or Z, and is defined as the logarithm of the 
odds in favor of linkage. The LOD score will test the linkage between two loci in what is 
known as a two-point analysis. A LOD score of 3 or greater is used to accept linkage between 
two loci, whereas a LOD score of –2 or less is used to exclude linkage. The values between 3 
and –2 are inconclusive and are not sufficient to prove any hypothesis (Fig. 8). LOD score 
calculations are performed using statistical computer software, such as LINKAGE76. These 
calculations are done assuming a particular inheritance pattern, disease allele frequency, 
penetrance, possibility of phenocopies, etc. This kind of analysis, where the model under 
study is specified, is known as parametric analysis. 
The use of more than one marker can be helpful, since a particular pedigree can be 
informative for different markers. The analysis of the data from different markers at a time is 
called multipoint analysis, as opposed to two-point analysis as described above. 
 
Fig. 8 Example of two-point LOD score values for markers on chromosome 1. 
 
6.1.2. Refinement of the Linkage Interval 
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The identification of the linkage interval is not the end of the work, but just the 
beginning. It gives us an idea of the most likely location for the disease gene. But these 
intervals are normally too large to work with, 5-10 cM, or even larger, with hundreds of 
genes. For this reason, the step of narrowing down the disease locus is essential, unless an 
obvious candidate gene maps to the initially identified interval. This refinement of the disease 
locus can be achieved by different means, including the finding of LOH or a chromosomal 
abnormality in a subset of patients. But for the vast majority of genetic diseases, this is not the 
case. 
As described above, in a genome-wide scan markers spaced at an average of 10 cM 
are used. But the genetic maps are much denser. Thus, once the disease interval has been 
identified, the best way to narrow it down is to increase the sample of individuals and the 
number of markers analyzed. 
In this step of the study, the analysis of haplotypes is essential to find recombinations 
that can further define the linkage interval. The goal is to define the boundaries of the smallest 
interval, defined by the closest markers that show recombination with the disease phenotype. 
When several close markers are analyzed, the disease gene will be linked to a certain 
haplotype, instead of a single marker. This disease-associated haplotype can include a 
different number of markers in different members of the family, since recombination events 
can break this shared haplotype along the generations in the pedigree. Once an individual is 
identified where a recombination has occurred inside the disease-associated haplotype, known 
as a key recombination event, this will reduce the region where the disease gene could be 
located (Fig. 9). By identifying different key recombinants, the most likely location of the 
disease gene can be narrowed down. 
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Fig. 9 Example of haplotype analysis for the refinement of a linkage interval. 
 
6.1.3. Positional Cloning and Positional Candidate Genes 
 
When the linkage interval cannot be further reduced, the identification of the actual 
disease gene begins. Traditionally, this had to be done by an arduous and not very fruitful 
positional cloning strategy, where different techniques to isolate genes were applied. 
Although this is still necessary in some instances, the information and resources available 
from the public and private Human Genome Project efforts have made the positional 
candidate approach the most powerful strategy. In a positional candidate gene approach, the 
candidates will specifically map to the disease locus interval. 
As a result of the public Human Genome Project effort, there are currently three 
internet servers providing free access to the up to date sequence data generated, National 
Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov), University of 
California, Santa Cruz (UCSC; http://genome.cse.ucsc.edu/) and Ensembl 
(http://www.ensembl.org/). The user can browse integrated maps where the physical location 
of different elements, such as polymorphic markers, known genes, predicted genes, ESTs 
(Expressed Sequence Tags), or STSs (Single Tagged Sites), among others, are shown. 
Eventually, the sequence and the position of all human genes will allow the analysis of all the 
genes contained in a disease interval. 
The identification of the genes responsible for Darier-White or Hailey-Hailey diseases 
are examples of positional candidate approaches (chapter 59). The genetic locus for the gene 
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underlying Darier-White disease was located to chromosome 12 by linkage analysis77,78. After 
refinement of the region, several genes were identified in the linkage interval. Among them, 
the ATP2A2 gene, encoding the calcium pump SERCA2, was considered a good candidate 
due to the role of calcium in epithelial junctions (defective in the epidermis of Darier-White 
patients) and cell differentiation. In fact, ATP2A2 was found to be mutated in Darier-White 
patients. 
In a separate study, linkage of the similar Hailey-Hailey disease phenotype had been 
established to chromosome 379. Fortunately, one gene in the linkage critical interval, ATP2C1, 
showed homology to calcium ATPases and, thus, it might have a function related to SERCA2. 
As expected, this gene turned out to be mutated in Hailey-Hailey patients80,81. 
Mouse models are also emerging as a powerful tool in the identification of disease 
genes. This approach relies on the existence of chromosomal regions that share the same 
origin in evolution, known as syntenic regions. Thus, once the genetic interval in human is 
identified, the syntenic interval in mouse can be analyzed to identify additional candidate 
genes. Also, if a similar phenotype in mouse has been mapped to this region and the mutated 
gene is known, this becomes an excellent candidate for the human disease counterpart, and 
viceversa. The identification of mutations in the hairless gene in patients with APL82 is a good 
example for mutations in the human, mouse, rat and monkey orthologous genes resulting in a 
very similar phenotype. 
If there are no obvious candidate genes in the region of interest or if none of the genes 
analyzed is the responsible for the disease, a positional cloning strategy will have to be 
performed for the identification of new genes in the interval. 
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6.1.4. Identification of Mutations 
 
Once a candidate gene is identified, its involvement in the disease has to be proven. 
This involves the identification of DNA variants present only in patients and absent in the 
control population. There are several techniques that can be initially used to search for 
mutations, such as SSCP (Single Strand Conformation Polymorphism) or CSGE 
(Conformation Sensitive Gel Electrophoresis). However, eventually all of them lead to the 
determination of the precise DNA sequence of the mutant allele. 
There are different types of mutations. Point mutations consist of the substitution of a 
single nucleotide position. This change can lead to an amino acid substitution in the case of a 
missense mutation, to the generation of a termination codon, nonsense, or to no change in the 
protein sequence, silent mutation. There can also be small duplications, insertions or 
deletions. If they affect a piece of the protein coding sequence that is not a multiple of three 
nucleotides (a codon), they will lead to a frameshift in the protein sequence and to the 
generation of a premature termination codon. These types of mutations can affect both coding 
and non-coding sequence, such as the promoter region, consensus splicing signals and other 
key intronic positions. Large rearrangements, such as partial or complete deletions of the 
entire gene, can also occur. 
It is important to note that some of these DNA mutations, especially missense and 
silent substitutions, can be non-pathogenetic variants, present in the general population as 
polymorphisms. 
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7. Complex Traits 
 
Classical Mendelian diseases, where a genetic defect in one single gene is enough for 
the disease to develop, are only a small number of genetic diseases. There are many common 
conditions that, although being heritable, are not due to a single-gene defect. Instead, they are 
thought to be determined by the interaction of multiple genetic factors among them and with 
the environment, as well. This combination of genetic factors usually confers only 
susceptibility to a certain disease, but cannot be used as a diagnostic tool by itself. Such traits 
are referred to as complex or multifactorial traits. They tend to cluster or aggregate in 
families, but they do not follow any Mendelian pattern of inheritance. 
As opposed to Mendelian traits, recurrence risk assessment for multifactorial traits is 
empirical, i.e., it is based on epidemiological data, where the real frequencies for different 
degree relatives have been determined. Some examples of dermatological complex traits are 
atopic dermatitis, eczema, psoriasis and alopecia areata (chapters 9, 13 and 69). The absence 
of any known Mendelian inheritance pattern can be observed when a collection of pedigrees 
with the same complex trait is analyzed at once, as shown in figure 10. 
 
Fig. 10 Pedigrees with alopecia areata as an example of multifactorial dermatological 
disease. 
 
Why, then, if Mendelian disorders are rather rare compared to the more common 
complex traits, have they been, and still are, the focus of much research in Human Genetics? 
The complex nature of a multifactorial trait increases the difficulty of gene identification. 
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Although similar techniques are used if compared to single gene defects, they require 
different methods to interpret the results. The initial goal in the study of complex traits is the 
identification of different DNA variants in different genes, each of them with a contribution to 
the final phenotype and conferring a degree of susceptibility to the carrier, instead of a 
mutation in a single gene. As it has already been shown for some diseases, these variants can 
also be present in the general population, although in a significantly different frequency. 
Large collections of patients need to be studied in order to identify a statistically significant 
contribution of a given genetic factor. As it has already been shown, these susceptibility 
variants could be present in genes responsible for similar Mendelian diseases. 
 As an example, homozygosis for the mutation W185X, in the PVLR1 gene, has been 
shown to cause autosomal recessive cleft lip/palate (CLP) with ectodermal dysplasia, very 
frequent on the Margarita island, north to Venezuela83. This same mutation has been shown to 
be overepresented among individuals with the multifactorial isolated CLP in northern 
Venezuela (5.8%), a, when compared to control individuals from the same population (0.4%). 
Although these results are highly significant, they constitute only a moderate genetic risk 
factor, since just a small number of CLP patients carry the mutation84,85. 
 Another example for the role of Mendelian gene disorders in related complex traits is 
the case of the gene SPINK5, recessive mutations in which cause Netherton disease, a skin 
disorder associated with atopy86,87. The authors have shown a statistically significant 
association between the amino acid variant Glu420Lys in the SPINK5 gene and atopy or 
atopic dermatitis87. Again, this does not mean that SPINK5 is responsible for atopic dermatitis, 
but it could shed some light into the etiology of AD and atopy. 
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 Studies like those described above underscore the value of the knowledge gathered 
from rare Mendelian disorders to derive important clues for more common related complex 
traits. In addition, the identification of genetic factors for multifactorial traits, although being 
just a susceptibility factor, can indicate unknown pathways susceptible for the development of 
targeted therapies and to a way to modify key environmental factors in these major public 
health issues. 
Disease gene identification is of chief importance not only for genetic counseling and 
prenatal diagnostic, but it is also the first step in the elucidation of the mechanisms underlying 
a disease and the eventual development of a suitable treatment. 
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Fig. 2 Examples of allelic heterogeneity in genodermatoses 
 
 Examples of allelic heterogeneity in genodermatoses 
 
 
Genea Phenotypeb Reference 
   GJB3 Erythrokeratodermia variabilis 5 
    AD nonsyndromic sensorineural deafness 6 
    AR nonsyndromic hearing loss  7 
    AD deafness with peripheral neuropathy 8 
   Desmoplakin Dermatosis palmoplantaris striata 9 
    Dilated cardiomyopathy with woolly hair and 
keratoderma 
10 
   Plectin EBS and limb-girdle muscular dystrophy 11,12 
    EBS of the Ogna type 13 
    
a GJB3: gene encoding connexin 30.3 
b AD: autosomal dominant; AR: autosomal recessive; EBS: epidermolysis bullosa simplex 
 
 
Fig. 3 Examples of genetic or locus heterogeneity in genodermatoses 
 
 Examples of genetic or locus heterogeneity in genodermatoses 
 
 
Phenotype Genea, b Reference 
   EBS Dowling-Meara variant KRT5 14 
    KRT14 15 
   EBS Koebner variant KRT5 16 
    KRT14 17 
   EBS Weber-Cockayne variant KRT5 18 
    KRT14 19 
   Hermansky-Pudlak syndrome HPS1 20,21 
    AP3B1 22 
    HPS3 23 
    HPS4 24 
    
a AP3B1: gene for beta-3A subunit of AB3; KRT5: keratin 5 gene; KRT14: keratin 14 gene 
b HPS1, HPS3 and HPS4: genetic loci or genes for Hermansky-Pudlak syndrome.  
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Fig. 1 Example of a polymorphic locus. Locus A represents a polymorphic locus with 
three different alleles. The example shows a family in which the father is homozygous for 
allele 1 and the mother is heterozygous for alleles 2 and 3. The son of this family has 
inherited alleles 1 from the father and 3 from the mother, and is, thus, heterozygous (2,3). 
 
Fig. 2 Examples of allelic heterogeneity in genodermatoses 
 
Fig. 3 Examples of genetic or locus heterogeneity in genodermatoses 
 
Fig. 4 Examples of Mendelian patterns of inheritance. A Autosomal dominant 
epidermolysis bullosa simplex superficialis (modified from ref. 29); B Autosomal 
recessive woolly hair, palmoplantar keratoderma and heart disease (modified from ref. 
30); C X-linked recessive immune deficiency and hypohidrotic ectodermal dysplasia 
(modified from ref. 31); D X-linked dominant incontinentia pigmenti (modified from ref. 
32); E Y-linked retinitis pigmentosa (modified from ref. 33). The symbols commonly used 
for pedigree drawing are indicated at the bottom of the figure. 
 
Fig. 5 Examples of complications to the basic Mendelian patterns of inheritance. A 
Reduced penetrance in a pedigree with autosomal dominant retinitis pigmentosa 
(modified from ref. 38); B High degree of consanguinity in a family with hypotrichosis, 
with affected family members in several generations; C Pseudodominant inheritance in 
autosomal recessive atrichia with papular lesions (APL). The inheritance of APL in this 
pedigree mimics an autosomal dominant pattern of inheritance resulting from the mating 
  2 
between a patient homozygous for the causative genetic mutation (II:2) and an unaffected 
carrier (modified from ref. 39). 
 
Fig. 6 Examples of haplotypes for a chromosomal region containing four 
polymorphic loci, A, B, C and D. 
 
Fig. 7 Examples of different types of polymorphisms. SNPs (A, B) consist of single 
base substitutions. Panel A shows a point substitution (underlined) replacing a cytosine, 
C, for a thymidine, T, identified by DNA sequencing. A polymorphism that affects the 
recognition site for a restriction enzyme is referred to as an RFLP (Restriction Fragment 
Length Polymorphism). In this particular example, the sequence ggatcc is the target site 
for the restriction enzyme BamHI. In the presence of this site, the enzyme will cut the 
DNA into two fragments, detected as two bands in an agarose gel; C Example of a 
microsatellite. The repeat unit of the microsatellite shown here is the dinucleotide (CA). 
The number of tandem repeats of the (CA) unit can vary in each allele. The figure shows 
two individuals heterozygous for this dinucleotide. The difference in length between 
these three alleles appears as bands of DNA of different sizes in a polyacrylamide gel. 
 
Fig. 8 Example of two-point LOD score values for markers on chromosome 1. Those 
values greater than 3 (in red) indicate linkage between the phenotype and the marker. The 
negative values for markers D1S209 and D1S2798 at a recombination fraction of 0 
indicate that genetic recombination has been observed between the phenotype and the 
marker. 
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Fig. 9 Example of haplotype analysis for the refinement of a linkage interval. The 
disease associated haplotype, 4 4 1 1 5 2 (shaded in blue) has been broken by genetic 
recombination in the family members (stars). The two key recombinant individuals, III:8 
and IV:1, have allowed the narrowing of the disease interval. 
 
Fig. 10 Pedigrees with alopecia areata as an example of multifactorial 
dermatological disease. Although some of the pedigrees individually can mimic 
Mendelian pattern of inheritance (C and D), others show a more complex pattern (A), in 
which the disease is inherited through two unrelated branches of the family. A single 
mode of inheritance cannot be established for the disease as a group. 
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